Please login to the form below

cardiovascular drug

This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

The investigational drug candidate met all primary and secondary endpoints in the phase 3 study, BMS said in a statement. ... address the underlying molecular defect of the disease,” said Roland Chen, senior vice president, cardiovascular development,

Latest news

Novartis’ canakinumab misses the mark in previously treated NSCLC

Previously, Novartis had attempted to expand the use of canakinumab as a potential cardiovascular treatment. ... This attempt failed to generate success, with Novartis pulling an EU filing for the drug in the cardiovascular setting in 2018.
CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

In December 2019, the US Food and Drug Administration (FDA) approved the drug with the brand name Vascepa, also to reduce the risk of cardiovascular events in high-risk patients. ... At that time, Vascepa became the first FDA-approved drug to reduce
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

Boehringer Ingelheim and Eli Lilly’s heart failure drug Jardiance reduced the risk of cardiovascular death or hospitalisation due to heart failure in adult patients with and without diabetes – an important ... In March, the US Food and Drug
Merck, Bayer get FDA priority review for heart failure drug

Even though the drug reduced hospitalisation, the difference in cardiovascular death and all-cause mortality between the groups was not significantly different. ... The New Drug Application (NDA) filed for vericiguat is aiming for approval as a treatment
Amarin shares tumble following Vascepa patent loss

It became the first US Food and Drug Administration (FDA)-approved drug to reduce cardiovascular risk in patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. ... treating indicated patients at high risk of

More from news
Approximately 2 fully matching, plus 100 partially matching documents found.

Latest Intelligence

Perfecting the pharmaceutical pipeline with AI

For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.
Going the distance

Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients
Interview: Peter Meeus, Novo Nordisk

Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.
Pharma deals during October 2012

In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... and manufacturing partner. Quillivant XR is based
Pharma deals during July 2012

These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Sanifit appoints Alexander Gold chief medical officer

Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug
Senior AstraZeneca exec jumps ship to small biotech

AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. . ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads
Milestone names chief medical officer

Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program
Jonathan Fox leaves AstraZeneca for MyoKardia

He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

New from the FDA: Diversity in clinical trials guidance summarised

For example, drug-drug interaction studies may enable those who currently take prescribed medicine to take part. ... For example, a clinical trial investigating a cardiovascular drug would specifically seek to enrol participants with risk factors for

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Principal Medical Writer: Varies on experience

Account Management: Competitive Salary Offered

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

PMHub

Add my company

Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....